GL — Q3 2026 Financial Report Analysis

Overview

Globe Life sells basic life insurance and supplemental health insurance, mostly to lower-middle and middle-income US households. In the third quarter of 2026 (July–September), total revenue rose 5.5% to $1.60 billion, but GAAP net income fell 6.9% to $361.1 million and diluted earnings per share (EPS) fell 2.3% to $4.62, from $4.73. The insurance business itself was steady in life and growing fast in health, but two problems in one small division, United American, turned its health book from a $16.1 million profit into a $6.4 million loss. That, plus larger investment losses and legal charges, pulled profit down — and it led management to cut full-year 2026 guidance to $15.35–$15.65 per share, from $15.55–$15.95 three months ago.

Net operating income — management's measure that strips out investment gains/losses and legal items — fell 3.9% to $378.8 million. Per share it edged up 0.6% to $4.84, only because buybacks shrank the diluted share count by 4.6% to 78.2 million.

Key metrics

Terms used above:

• Underwriting margin is what is left of premiums after paying claims and setting aside reserves ("policy obligations") and after the cost of selling the policies (commissions and acquisition costs). It shows how profitable the insurance itself is, before investment income, overhead, debt interest and tax.
• Net sales is the annual premium on newly issued policies, minus policies cancelled within 30 days. Premium revenue comes from everything already in force; net sales shows how fast new business is being added, so it signals where premium is heading.
• Excess investment income is net investment income minus the interest the company must credit to its policy reserves — the investment portfolio's actual profit.

Why the third quarter always looks different: the annual assumption update

Every third quarter Globe Life re-checks the assumptions behind its reserves (how many policyholders will die, fall sick or let their policies lapse) and books the result as a one-time "remeasurement" gain or loss. This year's update was a $120.5 million pre-tax gain ($96.4 million life, $24.1 million health), against $134.3 million a year ago ($130.9 million life, $3.4 million health). That is why Q3 earnings run well above other quarters, and why the year-over-year comparison of margins needs care:

• Life: reported underwriting margin fell 4.9% to $458.2 million, and its share of premium fell to 53% from 57%. Take out the assumption-update gains and the margin was about $361.8 million versus $350.7 million — up roughly 3% (our calculation from the release's figures). The decline is a smaller one-time gain, not a weaker life business. The release says the same about Liberty National (margin down 27% as reported, but 36.3% of premium versus 35.9% excluding the update).
• Health: reported margin rose 6.7% to $115.6 million. Take out the update and it was about $91.5 million versus $105.0 million — down roughly 13%. The reported increase is the accounting gain; the underlying health result got worse.

Health: fast growth, and a loss at United American

United American sells Medicare Supplement policies — private coverage for the costs original Medicare doesn't pay — through independent agents, and since the Evry Health acquisition it also runs a young group health business. Its premium rose 29% to $219.3 million and its health net sales nearly doubled (+95% to $47.7 million). But its underwriting margin swung to a $6.4 million loss (−3% of premium) from a $16.1 million profit (9%). The release attributes this to two items:

• an underwriting loss at Evry of about $16 million, from "high-severity claims" at a business management describes as "still growing and scaling to a size that will enable stable results"; and
• about $7 million of excess prior-period Medicare Supplement claims that landed this quarter because of a claims-processing delay at the Centers for Medicare and Medicaid Services (CMS).

The CMS item is a timing issue: claims from earlier periods were paid late and recorded now. The Evry loss is harder to dismiss: in Q2 the 10-Q already warned the group business "may produce volatile results," and this quarter it produced a loss roughly as large as all of United American's profit a year ago.

The rest of health was solid. Family Heritage (cancer and critical-illness policies) grew premium 8% to $128.6 million, underwriting margin 12% to $56.8 million (44% of premium) and net sales 5%. American Income's health margin jumped 155% to $37.9 million, but the release says that was mainly assumption updates (65.4% of premium excluding them, versus 59.7%).

Life: steady premium, mixed sales

• American Income (an exclusive agent force selling largely through labor unions and other affinity groups) is the biggest division. Premium grew 4% and its life margin 3% to $268.5 million (57% of premium). Net sales were flat, and the average producing agent count fell 7% year over year to 11,331 — and slipped from 11,391 in Q2. Management has said long-term sales growth in its agencies tracks the size of the agent force, so a flat-to-shrinking agency is the main limit on future life growth.
• Direct to Consumer (mail and online) net sales fell 12% to $24.0 million, after −15% in Q2. In the Q2 10-Q the company tied this to AI tools in consumer search reducing paid-search traffic. Premium slipped 1%, but its margin held at 47% of premium.
• Liberty National is the bright spot: 9% more agents, 7% higher life net sales, 4% higher premium.

Investments and capital

Net investment income rose 3.5% to $295.9 million, and excess investment income 2.9% to $37.9 million, because required interest on policy reserves (+4%) grew almost as fast as investment income (+3%). The bond portfolio yielded 5.33% versus 5.26% a year ago. The company bought $832.5 million of bonds this quarter (versus $279.3 million a year ago) at an average 6.4% yield and A rating, so new money is still going in above the portfolio average. 97% of fixed maturities are investment grade.

The bond portfolio shows a $2.69 billion net unrealized loss (fair value $16.87 billion versus $19.56 billion amortized cost). That is a rate effect on long-dated bonds the company generally holds to maturity; it runs through AOCI ("accumulated other comprehensive income," the part of equity that swings with market rates), not net income. Book value per share rose 23% to $85.35; excluding AOCI it rose 11% to $103.62.

Buybacks: 1.1 million shares for $185 million (average $175.61). Management raised its 2026 buyback plan to $725–$775 million, from $670–$700 million.

What the headline numbers hide

• GAAP vs operating EPS gap: $0.22 per share. Net operating income was $4.84 per share; GAAP EPS was $4.62. The gap is $0.13 of after-tax realized investment losses ($10.0 million, versus $3.9 million a year ago), $0.09 of legal-proceedings charges ($6.8 million after tax, versus $2.0 million), and $0.01 of other non-operating expenses. The earnings release does not say which matters the legal charge relates to, and the full 10-Q has not been filed yet.
• The one-off assumption-update gain shrank. $120.5 million this year versus $134.3 million last year, pre-tax. Total remeasurement gains, including the effect of actual versus expected claims, were $145.8 million versus $158.3 million. Both years' Q3 are inflated by these gains; the comparison between them is fair, but neither is a run-rate quarter.
• Per-share growth is all buybacks. Total net operating income fell 3.9%, yet per-share operating income rose 0.6% because diluted shares fell 4.6%. GAAP EPS fell 2.3% versus a 6.9% drop in net income for the same reason. The tax rate was 18.2% versus 18.7%, a small help.
• Expenses rose with premium. Administrative expenses were 7.3% of premium, same as a year ago.
• Guidance went down, not up. In Q2 the range was raised to $15.55–$15.95; it is now $15.35–$15.65. Management says the cut reflects the two United American items "rather than a fundamental change in our underlying core business." The life numbers above support that for life; the health numbers show the Evry problem is real money.
• Regulatory and litigation scrutiny. Globe Life's sales practices have drawn short-seller allegations and government inquiries in the past. The earnings release gives no update on any of them; the only sign in the numbers is the larger $6.8 million legal-proceedings charge. Watch the Q3 10-Q's legal proceedings note for what it covers.

Did last time's read hold up?

Mostly not in the company's favor. Our Q2 report said to watch whether American Income's agent count kept recovering from its Q1 low (11,064): it rose to 11,391 in Q2 but slipped to 11,331 in Q3, so the recovery stalled. Direct to Consumer sales were still falling (−12% after −15%). We also expected United American to keep adding premium "at low margins"; it added premium (+29%) but its margin turned negative. And the full-year guidance that was raised in Q2 has now been cut.

Takeaway: Globe Life's life insurance business is earning a bit more per policy than a year ago once the annual accounting gain is set aside, but its growth engine has moved to health, and the newest piece of that — Evry's group health business — lost about $16 million in one quarter. Per-share earnings are being held up by buybacks while the agent force that drives life sales is no longer growing.

Outlook

Management now expects 2026 net operating income of $15.35–$15.65 per share. With $11.88 earned through nine months ($7.04 in the first half plus $4.84 in Q3), that implies roughly $3.47–$3.77 in Q4, a quarter without the Q3 assumption-update boost. For 2027 it guides to $16.10–$17.10, 7.1% above the new 2026 midpoint, and it will spend $725–$775 million on buybacks this year.

Our view: the 2027 range assumes the United American problems are temporary. The CMS delay should be — it is late-booked claims, not more claims. Evry is the open question: a business still "scaling to a size that will enable stable results" can keep producing lumpy losses, and the release gives no target date for that. On the life side, the forecast depends on American Income's agent count, which fell 7% year over year and did not grow from Q2. Until agent recruiting turns up, expect life premium growth around 2–4% and per-share growth that leans heavily on buybacks. The things to watch in Q4: whether United American's health margin returns to positive, whether American Income's agent count grows again, and what the 10-Q says about the legal-proceedings charge.

Source: Globe Life Q3 2026 earnings release (Form 8-K Exhibit 99.1, October 21, 2026). The full Q3 10-Q, with segment MD&A detail, had not been filed at the time of writing.